INCRUSE ELLIPTA
LAMA DPI
Umeclidinium bromide · GlaxoSmithKline
Active Medication & Mechanism
- Umeclidinium bromide LAMA62.5 mcg per blister
Long-acting muscarinic antagonist (anticholinergic). Competitively and reversibly inhibits M3 receptors on airway smooth muscle, preventing acetylcholine-induced bronchoconstriction.
FDA-Approved Dosing — Strength × Indication
Strength Regimen COPDAsthma
62.5 mcg
1 inhalation once daily → 62.5 mcg
FDA Approved
Long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD.
Not Approved
Incruse Ellipta is NOT indicated for asthma.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
62.5 mcg 1 inhalation once daily → 62.5 mcg
COPD FDA Approved
Long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD.
Asthma Not Approved
Incruse Ellipta is NOT indicated for asthma.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
Not a rescue inhaler. Not for acute bronchospasm. Use a SABA.